Journal article
SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication
JT Denholm, ES McBryde, D Eisen, A Street, E Matchett, C Chen, T Shultz, B Biggs, K Leder
Internal Medicine Journal | WILEY | Published : 2017
DOI: 10.1111/imj.13601
Abstract
Background: Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9-month course of isoniazid (9H). A 3-month course of weekly isoniazid and rifapentine (3HP) has been shown to be as effective as 9 months of daily isoniazid, and associated with less hepatotoxicity; however, rifapentine is not currently available in Australia. Introduction of this regimen would have apparent advantages for people with LTBI in Victoria by safely shortening duration of LTBI therapy. However, the cost benefit of this new therapeutic approach is uncertain. Aim: Cost-analysis of standard and short-course therapy for LTBI in an Australian context. Methods: Single-cent..
View full abstractGrants
Funding Acknowledgements
This study was provided through a grant by the John Burge Trust, administered by the State Trustees of Victoria. Rifapentine was provided by Sanofi. Neither organisation played a role in study design, conduct, analysis or manuscript preparation.